Arlene O. Siefker‐Radtke
A5057758356- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Fibroblast Growth Factor Research
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Renal cell carcinoma treatment
- Urological Disorders and Treatments
- Multiple and Secondary Primary Cancers
- Lung Cancer Research Studies
- Adenosine and Purinergic Signaling
- Advanced Breast Cancer Therapies
- Neuroendocrine Tumor Research Advances
- Ferroptosis and cancer prognosis
- Metastasis and carcinoma case studies
- Esophageal Cancer Research and Treatment
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- RNA modifications and cancer
- Immune Cell Function and Interaction
- Cancer-related molecular mechanisms research
- Viral-associated cancers and disorders
- Infectious Disease Case Reports and Treatments
- Genetic factors in colorectal cancer
- Prostate Cancer Treatment and Research
The University of Texas MD Anderson Cancer Center
2016-2025
University of Houston
2021
Fred Hutch Cancer Center
2018
Stanford University
2018
Cancer Research Center
2018
University Hospitals Seidman Cancer Center
2016-2017
Cancer Institute (WIA)
2017
University of Alabama at Birmingham
2017
Spanish Oncology Genitourinary Group
2005-2017
Cleveland Clinic
2017
Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase inhibitor of FGFR1–4, has shown antitumor activity preclinical models phase 1 study involving patients FGFR alterations.
Muscle-invasive bladder cancer (MIBC) is a molecularly diverse disease with heterogeneous clinical outcomes. Several molecular classifications have been proposed, but the diversity of their subtype sets impedes application. To achieve an international consensus on MIBC subtypes that reconciles published classification schemes. We used 1750 transcriptomic profiles from 16 datasets and two additional cohorts. performed network-based analysis six independent systems to identify set classes....
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on clinical presentation and workup of suspected bladder cancer, treatment non–muscle-invasive urothelial metastatic cancer because important updates have recently been made to these sections. Some include recommendations optimal event a bacillus Calmette-Guérin (BCG) shortage details about biomarker testing advanced or disease. The systemic therapy second-line subsequent...
The epithelial-to-mesenchymal transition (EMT) is a cell development-regulated process in which noncoding RNAs act as crucial modulators. Recent studies have implied that EMT may contribute to resistance epidermal growth factor receptor (EGFR)-directed therapy. aims of this study were determine the potential role microRNAs (miRNA) controlling and inducing sensitivity human bladder cancer cells inhibitory effects anti-EGFR therapy.miRNA array screening real-time reverse transcription-PCR used...
Cancers infiltrated with T-cells are associated a higher likelihood of response to PD-1/PD-L1 blockade. Counterintuitively, correlation between epithelial-mesenchymal transition (EMT)-related gene expression and T-cell infiltration has been observed across tumor types. Here we demonstrate, using The Cancer Genome Atlas (TCGA) urothelial cancer dataset, that although expression-based measure infiltrating abundance EMT-related positively correlated, these signatures convey disparate prognostic...
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy muscle-invasive urothelial bladder cancer, as substantial revisions were made 2017 updates, such new recommendations nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of addresses additional aspects management including non-muscle-invasive cancer nonurothelial histologies, well staging, evaluation, follow-up.
The NCCN Guidelines for Bladder Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer other urinary tract cancers (upper tumors, urothelial carcinoma prostate, primary urethra). These Insights summarize panel discussion behind recent important updates to guidelines regarding treatment non–muscle-invasive cancer, including how treat in event a bacillus Calmette-Guérin (BCG) shortage; new roles immune checkpoint inhibitors non–muscle...
CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated nivolumab 3 mg/kg monotherapy every 2 weeks (NIVO3), plus ipilimumab 1 for four doses followed by (NIVO3+IPI1), (NIVO1+IPI3). We report on the expanded NIVO1+IPI3 cohort and extended follow-up NIVO3 NIVO3+IPI1 cohorts.Patients platinum-pretreated mUC were enrolled in this phase I/II multicenter to receive NIVO3, NIVO3+IPI1, until disease...
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These Insights discuss important updates to 2018 version guidelines, including implications 8th edition AJCC Staging Manual on treatment muscle-invasive cancer incorporating newly approved immune checkpoint inhibitor therapies into options locally advanced or metastatic disease.
Abstract Immune checkpoint therapy (ICT) provides substantial clinical benefits to cancer patients, but a large proportion of cancers do not respond ICT. To date, the genomic underpinnings primary resistance ICT remain elusive. Here, we performed immunogenomic analysis data from TCGA and trials anti-PD-1/PD-L1 therapy, with particular focus on homozygous deletion 9p21.3 (9p21 loss), one most frequent defects occurring in ~13% all cancers. We demonstrate that 9p21 loss confers “cold”...
Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2 alterations who have progression after platinum-containing chemotherapy. The effects erdafitinib patients FGFR-altered during checkpoint inhibitors (anti-programmed cell death protein 1 [PD-1] anti-programmed ligand [PD-L1] agents) are unclear. We conducted global phase 3 trial as compared chemotherapy had...
Bladder cancer, the sixth most common cancer in United States, is commonly of urothelial carcinoma histologic subtype. The clinical spectrum bladder divided into 3 categories that differ prognosis, management, and therapeutic aims: (1) non-muscle-invasive (NMIBC); (2) muscle invasive, nonmetastatic disease; (3) metastatic cancer. These NCCN Guidelines Insights detail recent updates to for Cancer, including changes fifth edition WHO Classification Tumours: Urinary Male Genital Tumours how...
No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Apr 2003Multimodality Management Urachal Carcinoma: The M. D. Anderson Cancer Center Experience ARLENE O. SIEFKER-RADTKE, JASON GEE, Y.U. SHEN, SIJIN WEN, DANAI DALIANI, RANDALL E. MILLIKAN, and LOUIS L. PISTERS SIEFKER-RADTKEARLENE SIEFKER-RADTKE , GEEJASON GEE SHENY.U. SHEN WENSIJIN WEN DALIANIDANAI DALIANI MILLIKANRANDALL MILLIKAN PISTERSLOUIS View All Author...
Abstract BACKGROUND: The authors evaluated the incidence of pathologic downstaging and complete remission (CR) in patients with high‐grade ureteral renal pelvic transitional cell carcinoma (TCC) (upper tract TCC) who received neoadjuvant chemotherapy followed by surgery. METHODS: study group comprised biopsy‐demonstrated, disease nephrouterectomy from 2004 to 2008, during which time uniformly were considered for chemotherapy. control underwent initial nephroureterectomy 1993 2004, when...